Affordable Access

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.

Authors
Type
Published Article
Journal
Clinical Neurology and Neurosurgery
0303-8467
Publisher
Elsevier
Publication Date
Volume
108
Issue
2
Pages
124–128
Identifiers
PMID: 16412833
Source
Medline

Abstract

Our result shows that RRMS patients have an impaired MMP-9 and TIMP-1 balance, and that 6 months of IFNbeta therapy is beneficial in restoring this balance.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F